BridgeBio Pharma, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+5.97%
vs ±10.2% implied · ×0.58
shaded = implied · ▲▼ = realized
BridgeBio Pharma has 2 disclosed suppliers and 6 disclosed customers in SEC filings.
BridgeBio Pharma, Inc.
74.74
SentenceIn January 2018, through our subsidiary QED, we entered into a license agreement with Novartis International Pharmaceutical Ltd. ("Novartis"), for certain intellectual property rights, including patents and know-how, related to infigratinib for the treatment of patients with FGFR-driven diseases, including achondroplasia and hypochondroplasia.
SentenceIn April 2016, through Eidos, we entered into an exclusive license agreement with Stanford for rights relating to novel transthyretin aggregation inhibitors.
BBIO 10-Kaccession 0001743881-26-000009
SentenceWe have licensed commercial rights in Japan to Alexion, AstraZeneca Rare Disease, under the Exclusive License Agreement signed in September 2019 with our subsidiary, Eidos Therapeutics, Inc.
BBIO 10-Kaccession 0001743881-26-000009
In September 2019, Eidos, entered into an exclusive license agreement with Alexion Pharma International Operations Limited Company, a subsidiary of Alexion Pharmaceuticals, Inc. (together, "Alexion") (the "Eidos-Alexion License Agreement"), to develop, manufacture, and commercialize in Japan the compound known as acoramidis (previously known as AG10) and any of its various chemical forms and any pharmaceutical products containing acoramidis.
BBIO 10-Kaccession 0001743881-26-000009
SentenceWe have licensed commercial rights in Europe to Bayer who are commercializing Beyonttra in all EU member states, the United Kingdom, Switzerland and Turkey under our Exclusive License Agreement with Bayer signed in March 2024.
BBIO 10-Kaccession 0001743881-26-000009
SentenceOn March 1, 2024, our subsidiaries, Eidos, BridgeBio International GmbH and BridgeBio Europe B.V. (collectively, "the Seller Parties"), entered into an exclusive license agreement (the "Bayer License Agreement") with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG ("Bayer"), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the EU and all member and extension states of the European Patent Organization (the "Licensed Territory").
BBIO 10-Kaccession 0001743881-26-000009
SentenceOn February 7, 2024, the Company's subsidiary, QED, and Kyowa Kirin Co., Ltd ("Kyowa Kirin" or "KKC") entered into a license and collaboration agreement pursuant to which QED granted Kyowa Kirin an exclusive license to develop, manufacture, and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan, in accordance with the terms therein (the "KKC License Agreement").
BBIO 10-Kaccession 0001743881-26-000009
SentenceIn March 2022, Sentynl Therapeutics, Inc. acquired global rights to NULIBRY and assumed responsibility for its ongoing development, manufacturing, and commercialization worldwide.
BBIO 10-Kaccession 0001743881-26-000009
Linked news
NewsExpected move
Inputsspot 74.95exp Jan 15ATM strike 75ATM straddle 12.45IV 46%